Patient and prescriber characteristics among patients with type 2 diabetes mellitus continuing or discontinuing sulfonylureas following insulin initiation: data from a large commercial database.
Daniel C BeachlerGail FernandesGaurav DeshpandeJamileh JemisonJennifer G LyonsStephan LanesJinan LiuAnnie McNeillPublished in: Current medical research and opinion (2018)
Roughly half of commercially-insured T2DM patients discontinued SU within 1 year after insulin initiation, and SU discontinuation was not strongly associated with a range of patient and provider characteristics.